SynthesisEndocrine2020

GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.

Chuqing Cao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.